+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs for the Treatment of Refractory Gout Market - Global Forecast 2026-2032- Product Image
Drugs for the Treatment of Refractory Gout Market - Global Forecast 2026-2032- Product Image
Sale

Drugs for the Treatment of Refractory Gout Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6081639
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Drugs for the Treatment of Refractory Gout Market is projected to reach USD 3.47 Billion in 2026. It is expected to continue growing at a CAGR of 7.92%, reaching USD 5.48 Billion by 2032.

Refractory Gout Treatment: Executive Overview

Refractory gout is characterized by persistent hyperuricemia and clinically significant disease despite conventional urate-lowering therapy, often alongside recurrent flares, tophi, joint damage, and functional impairment. Treatment decisions require confirmation of diagnosis, assessment of treatment adherence and comorbidities, and sustained urate monitoring. The therapeutic landscape includes intensified urate-lowering strategies, anti-inflammatory management, and specialist-directed options for patients whose disease remains inadequately controlled.

Treatment Is Shifting Toward Sustained Disease Control

Care is moving from episodic flare suppression toward long-term control of urate burden and crystal deposition. Greater attention to treat-to-target monitoring, dose optimization, renal and cardiovascular risk assessment, medication adherence, and patient education is reshaping clinical pathways. Refractory cases also highlight the importance of coordinated rheumatology, primary-care, nephrology, and pharmacy support, particularly when treatment complexity or comorbidity limits conventional options.

Artificial Intelligence Supports Diagnosis, Monitoring, and Personalization

Artificial intelligence can contribute to refractory gout care by supporting image interpretation, identifying patients at risk of recurrent flares, and analyzing longitudinal laboratory, medication, and clinical data. Decision-support tools may help clinicians recognize treatment gaps, flag potential adherence or interaction concerns, and personalize monitoring intervals. These applications remain dependent on representative data, clinical validation, transparent governance, and safeguards against automation bias; they should complement rather than replace specialist judgment.

Regional Patterns Reflect Access, Comorbidity, and Care Infrastructure

North America combines advanced specialty care with substantial variation in affordability, adherence, and access to rheumatology services. Latin America faces uneven diagnostic and treatment availability, with care shaped by public-sector capacity and medicine access. Europe benefits from established clinical guidance and health-system infrastructure, although reimbursement and national pathways differ. The Middle East shows expanding specialty capacity alongside heterogeneous access and high burdens of metabolic comorbidity. Africa continues to face gaps in diagnosis, laboratory monitoring, and specialist availability. Asia-Pacific presents wide contrasts between highly developed systems and settings where delayed diagnosis, limited specialty care, and affordability remain important barriers.

Economic and Political Groups Show Uneven Treatment Capacity

ASEAN markets differ materially in reimbursement, specialist density, laboratory access, and availability of advanced therapies, making regional implementation uneven. BRICS economies combine large and diverse patient populations with contrasting public-health capacity, urban access, and treatment affordability. The European Union benefits from shared scientific and regulatory cooperation, but national reimbursement and prescribing practices remain distinct. G7 systems generally have stronger specialist infrastructure and data capabilities, while facing cost, aging-population, and care-coordination pressures. GCC countries often possess comparatively strong hospital infrastructure but vary in workforce depth and reliance on centralized care. NATO members span multiple health-system models, so common security and research links do not eliminate differences in clinical access or reimbursement.

Country-Level Priorities Span Access, Monitoring, and Specialist Care

Australia emphasizes coordinated specialist management across geographically dispersed populations. Brazil and Mexico continue to face regional disparities in diagnosis, public-sector access, and continuity of monitoring. Canada and the United States have substantial specialist capability, but affordability, insurance design, and access outside major centers influence treatment continuity. China and India must address large population needs alongside pronounced urban-rural differences in specialist and laboratory access. Japan, South Korea, France, Germany, Italy, and Spain operate mature clinical systems, with variation in reimbursement, referral pathways, and uptake of advanced therapies. The United Kingdom combines structured guidance with ongoing pressure on specialist capacity and timely referral. Russia faces geographic and infrastructure challenges that can affect continuity of specialist-led care.

Prioritize Treat-to-Target Pathways and Equitable Specialist Access

Industry leaders should support evidence-based pathways that link diagnosis, urate measurement, dose optimization, flare prevention, and follow-up into a single care process. Educational initiatives should address adherence, shared decision-making, medication safety, and recognition of treatment failure. Access strategies should reflect local reimbursement and distribution realities rather than assume uniform availability. Partnerships with clinicians and health systems can improve laboratory monitoring and referral pathways, while real-world evidence programs should evaluate persistence, safety, quality of life, and outcomes across comorbidity and demographic groups. Digital and AI tools should be introduced with prospective validation, privacy controls, and clear clinician accountability.

Methodology: Evidence Synthesis Across Clinical and Health-System Dimensions

This executive summary uses the defined market scope of drugs for the treatment of refractory gout and organizes evidence around disease burden, treatment pathways, access conditions, regional variation, and health-system implementation. The approach should triangulate peer-reviewed clinical literature, treatment guidelines, regulatory documents, pharmacovigilance evidence, health-technology assessments, reimbursement policies, and publicly available health-system data. Findings should be interpreted qualitatively because treatment availability, diagnostic practices, and reporting standards vary across geographies. AI-related observations are framed as potential applications requiring clinical validation, not as established outcomes.

Sustained Control Depends on Integrated, Evidence-Led Care

The refractory gout treatment landscape is being shaped by the need for durable urate control, safer long-term management, and more equitable access to specialist support. Progress will depend on combining validated therapies with adherence-centered care, reliable monitoring, coordinated referrals, and locally appropriate reimbursement strategies. Regional and country differences make implementation context essential. Leaders that prioritize clinical evidence, responsible data use, and measurable patient outcomes will be better positioned to improve care for people whose disease remains uncontrolled with conventional management.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Drugs for the Treatment of Refractory Gout Market, by Mechanism Of Action
7.1. Introduction
7.2. Uricase Agents
7.2.1. Non-Pegylated Uricase
7.2.2. Pegylated Uricase
7.3. Uricosuric Agents
7.3.1. Benzbromarone
7.3.2. Lesinurad
7.3.3. Probenecid
7.4. Xanthine Oxidase Inhibitors
7.4.1. Allopurinol
7.4.2. Febuxostat
7.4.3. Topiroxostat
8. Drugs for the Treatment of Refractory Gout Market, by Product Type
8.1. Introduction
8.2. Branded
8.2.1. Biosimilar
8.2.2. Originator
9. Drugs for the Treatment of Refractory Gout Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.2.1. Bolus Injection
9.2.2. Infusion
9.3. Oral
9.3.1. Capsules
9.3.2. Tablets
9.4. Subcutaneous
9.4.1. Auto-Injector
9.4.2. Pre-Filled Syringe
10. Drugs for the Treatment of Refractory Gout Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.2.1. Inpatient
10.2.2. Outpatient
10.3. Online Pharmacy
10.3.1. Direct To Patient
10.3.2. E Pharmacy
10.4. Retail Pharmacy
10.4.1. Chain
10.4.2. Independent
10.5. Specialty Pharmacy
10.5.1. Closed Network
10.5.2. Open Network
11. Drugs for the Treatment of Refractory Gout Market, by Dosage Form
11.1. Introduction
11.2. Capsule
11.2.1. Hard Gelatin
11.2.2. Hpmc
11.3. Pre Filled Syringe
11.3.1. Glass
11.3.2. Polymer
11.4. Tablet
11.4.1. Film Coated
11.4.2. Immediate Release
11.5. Vial
11.5.1. Multi Dose
11.5.2. Single Dose
12. Drugs for the Treatment of Refractory Gout Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Drugs for the Treatment of Refractory Gout Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Drugs for the Treatment of Refractory Gout Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Amgen Inc.
16.2. Arthrosi Therapeutics, Inc.
16.3. AstraZeneca plc
16.4. Atom Bioscience and Pharmaceutical Co., Ltd.
16.5. Cartesian Therapeutics, Inc.
16.6. GlaxoSmithKline plc
16.7. InventisBio, Inc.
16.8. JW Pharmaceutical Corporation
16.9. Merck & Co., Inc.
16.10. Novartis AG
16.11. Olatec Therapeutics LLC
16.12. Pfizer Inc.
16.13. Protalix BioTherapeutics, Inc.
16.14. Regeneron Pharmaceuticals, Inc.
16.15. Sanofi S.A.
16.16. Shanton Pharma, Inc.
16.17. Swedish Orphan Biovitrum AB
16.18. Takeda Pharmaceutical Company Limited
16.19. Teijin Pharma Limited
16.20. XORTX Therapeutics Inc.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Drugs for the Treatment of Refractory Gout Market, Years Considered for the Study
FIGURE 2. Global Drugs for the Treatment of Refractory Gout Market, Research Design
FIGURE 3. Global Drugs for the Treatment of Refractory Gout Market, Research Framework
FIGURE 4. Global Drugs for the Treatment of Refractory Gout Market, Data Triangulation
FIGURE 5. Global Drugs for the Treatment of Refractory Gout Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Drugs for the Treatment of Refractory Gout Market Size, by Mechanism Of Action, 2025 vs 2032 (%)
FIGURE 7. Global Drugs for the Treatment of Refractory Gout Market Size, by Mechanism Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Drugs for the Treatment of Refractory Gout Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 9. Global Drugs for the Treatment of Refractory Gout Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Drugs for the Treatment of Refractory Gout Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Drugs for the Treatment of Refractory Gout Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Drugs for the Treatment of Refractory Gout Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Drugs for the Treatment of Refractory Gout Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Drugs for the Treatment of Refractory Gout Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 15. Global Drugs for the Treatment of Refractory Gout Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Drugs for the Treatment of Refractory Gout Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Drugs for the Treatment of Refractory Gout Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Drugs for the Treatment of Refractory Gout Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Drugs for the Treatment of Refractory Gout Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Drugs for the Treatment of Refractory Gout Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Drugs for the Treatment of Refractory Gout Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Drugs for the Treatment of Refractory Gout Market Segmentation & Coverage
TABLE 2. Global Drugs for the Treatment of Refractory Gout Market Size, 2017-2032 (USD Million)
TABLE 3. Global Drugs for the Treatment of Refractory Gout Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 4. Global Uricase Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Uricase Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Uricase Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Non-Pegylated Uricase Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Non-Pegylated Uricase Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Non-Pegylated Uricase Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Pegylated Uricase Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Pegylated Uricase Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Pegylated Uricase Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Uricosuric Agents Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Uricosuric Agents Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Uricosuric Agents Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Benzbromarone Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Benzbromarone Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Benzbromarone Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Lesinurad Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Lesinurad Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Lesinurad Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Probenecid Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Probenecid Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Probenecid Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Xanthine Oxidase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Xanthine Oxidase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Xanthine Oxidase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Allopurinol Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Allopurinol Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Allopurinol Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Febuxostat Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Febuxostat Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Febuxostat Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Topiroxostat Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Topiroxostat Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Topiroxostat Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Drugs for the Treatment of Refractory Gout Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 38. Global Branded Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Branded Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Branded Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Biosimilar Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Biosimilar Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Biosimilar Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Originator Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Originator Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Originator Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Drugs for the Treatment of Refractory Gout Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 48. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Bolus Injection Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Bolus Injection Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Bolus Injection Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Infusion Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Infusion Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Infusion Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Capsules Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global Capsules Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global Capsules Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Auto-Injector Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Auto-Injector Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Auto-Injector Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Pre-Filled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Pre-Filled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Pre-Filled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Drugs for the Treatment of Refractory Gout Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 76. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Inpatient Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Inpatient Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Inpatient Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Outpatient Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Outpatient Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Outpatient Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Direct To Patient Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Global Direct To Patient Market Size, by Group, 2017-2032 (USD Million)
TABLE 90. Global Direct To Patient Market Size, by Country, 2017-2032 (USD Million)
TABLE 91. Global E Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 92. Global E Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 93. Global E Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 94. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Chain Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Chain Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Chain Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Independent Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Independent Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Independent Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Closed Network Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Closed Network Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Closed Network Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Open Network Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Open Network Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Open Network Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Drugs for the Treatment of Refractory Gout Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 113. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
TABLE 115. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
TABLE 116. Global Hard Gelatin Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Global Hard Gelatin Market Size, by Group, 2017-2032 (USD Million)
TABLE 118. Global Hard Gelatin Market Size, by Country, 2017-2032 (USD Million)
TABLE 119. Global Hpmc Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Global Hpmc Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. Global Hpmc Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. Global Pre Filled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Pre Filled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Pre Filled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global Glass Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Glass Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Glass Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Polymer Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global Polymer Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global Polymer Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 134. Global Film Coated Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. Global Film Coated Market Size, by Group, 2017-2032 (USD Million)
TABLE 136. Global Film Coated Market Size, by Country, 2017-2032 (USD Million)
TABLE 137. Global Immediate Release Market Size, by Region, 2017-2032 (USD Million)
TABLE 138. Global Immediate Release Market Size, by Group, 2017-2032 (USD Million)
TABLE 139. Global Immediate Release Market Size, by Country, 2017-2032 (USD Million)
TABLE 140. Global Vial Market Size, by Region, 2017-2032 (USD Million)
TABLE 141. Global Vial Market Size, by Group, 2017-2032 (USD Million)
TABLE 142. Global Vial Market Size, by Country, 2017-2032 (USD Million)
TABLE 143. Global Multi Dose Market Size, by Region, 2017-2032 (USD Million)
TABLE 144. Global Multi Dose Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. Global Multi Dose Market Size, by Country, 2017-2032 (USD Million)
TABLE 146. Global Single Dose Market Size, by Region, 2017-2032 (USD Million)
TABLE 147. Global Single Dose Market Size, by Group, 2017-2032 (USD Million)
TABLE 148. Global Single Dose Market Size, by Country, 2017-2032 (USD Million)
TABLE 149. Global Drugs for the Treatment of Refractory Gout Market Size, by Region, 2017-2032 (USD Million)
TABLE 150. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Region, 2017-2032 (USD Million)
TABLE 151. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 152. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Uricase Agents, 2017-2032 (USD Million)
TABLE 153. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 154. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 155. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 156. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Branded, 2017-2032 (USD Million)
TABLE 157. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 158. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 159. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Oral, 2017-2032 (USD Million)
TABLE 160. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 161. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 162. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 163. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 164. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 165. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 166. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 167. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Capsule, 2017-2032 (USD Million)
TABLE 168. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Pre Filled Syringe, 2017-2032 (USD Million)
TABLE 169. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 170. Asia-Pacific Drugs for the Treatment of Refractory Gout Market Size, by Vial, 2017-2032 (USD Million)
TABLE 171. North America Drugs for the Treatment of Refractory Gout Market Size, by Region, 2017-2032 (USD Million)
TABLE 172. North America Drugs for the Treatment of Refractory Gout Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 173. North America Drugs for the Treatment of Refractory Gout Market Size, by Uricase Agents, 2017-2032 (USD Million)
TABLE 174. North America Drugs for the Treatment of Refractory Gout Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 175. North America Drugs for the Treatment of Refractory Gout Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 176. North America Drugs for the Treatment of Refractory Gout Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 177. North America Drugs for the Treatment of Refractory Gout Market Size, by Branded, 2017-2032 (USD Million)
TABLE 178. North America Drugs for the Treatment of Refractory Gout Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 179. North America Drugs for the Treatment of Refractory Gout Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 180. North America Drugs for the Treatment of Refractory Gout Market Size, by Oral, 2017-2032 (USD Million)
TABLE 181. North America Drugs for the Treatment of Refractory Gout Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 182. North America Drugs for the Treatment of Refractory Gout Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 183. North America Drugs for the Treatment of Refractory Gout Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 184. North America Drugs for the Treatment of Refractory Gout Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 185. North America Drugs for the Treatment of Refractory Gout Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 186. North America Drugs for the Treatment of Refractory Gout Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 187. North America Drugs for the Treatment of Refractory Gout Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 188. North America Drugs for the Treatment of Refractory Gout Market Size, by Capsule, 2017-2032 (USD Million)
TABLE 189. North America Drugs for the Treatment of Refractory Gout Market Size, by Pre Filled Syringe, 2017-2032 (USD Million)
TABLE 190. North America Drugs for the Treatment of Refractory Gout Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 191. North America Drugs for the Treatment of Refractory Gout Market Size, by Vial, 2017-2032 (USD Million)
TABLE 192. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Region, 2017-2032 (USD Million)
TABLE 193. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 194. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Uricase Agents, 2017-2032 (USD Million)
TABLE 195. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 196. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 197. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 198. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Branded, 2017-2032 (USD Million)
TABLE 199. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 200. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 201. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Oral, 2017-2032 (USD Million)
TABLE 202. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 203. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 205. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 206. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 207. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 208. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 209. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Capsule, 2017-2032 (USD Million)
TABLE 210. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Pre Filled Syringe, 2017-2032 (USD Million)
TABLE 211. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 212. Latin America Drugs for the Treatment of Refractory Gout Market Size, by Vial, 2017-2032 (USD Million)
TABLE 213. Europe Drugs for the Treatment of Refractory Gout Market Size, by Region, 2017-2032 (USD Million)
TABLE 214. Europe Drugs for the Treatment of Refractory Gout Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 215. Europe Drugs for the Treatment of Refractory Gout Market Size, by Uricase Agents, 2017-2032 (USD Million)
TABLE 216. Europe Drugs for the Treatment of Refractory Gout Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 217. Europe Drugs for the Treatment of Refractory Gout Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 218. Europe Drugs for the Treatment of Refractory Gout Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 219. Europe Drugs for the Treatment of Refractory Gout Market Size, by Branded, 2017-2032 (USD Million)
TABLE 220. Europe Drugs for the Treatment of Refractory Gout Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 221. Europe Drugs for the Treatment of Refractory Gout Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 222. Europe Drugs for the Treatment of Refractory Gout Market Size, by Oral, 2017-2032 (USD Million)
TABLE 223. Europe Drugs for the Treatment of Refractory Gout Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 224. Europe Drugs for the Treatment of Refractory Gout Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 225. Europe Drugs for the Treatment of Refractory Gout Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 226. Europe Drugs for the Treatment of Refractory Gout Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 227. Europe Drugs for the Treatment of Refractory Gout Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 228. Europe Drugs for the Treatment of Refractory Gout Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 229. Europe Drugs for the Treatment of Refractory Gout Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 230. Europe Drugs for the Treatment of Refractory Gout Market Size, by Capsule, 2017-2032 (USD Million)
TABLE 231. Europe Drugs for the Treatment of Refractory Gout Market Size, by Pre Filled Syringe, 2017-2032 (USD Million)
TABLE 232. Europe Drugs for the Treatment of Refractory Gout Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 233. Europe Drugs for the Treatment of Refractory Gout Market Size, by Vial, 2017-2032 (USD Million)
TABLE 234. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Region, 2017-2032 (USD Million)
TABLE 235. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 236. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Uricase Agents, 2017-2032 (USD Million)
TABLE 237. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 238. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 239. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 240. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Branded, 2017-2032 (USD Million)
TABLE 241. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 242. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 243. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Oral, 2017-2032 (USD Million)
TABLE 244. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 245. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 246. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 247. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 248. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 249. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 250. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 251. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Capsule, 2017-2032 (USD Million)
TABLE 252. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Pre Filled Syringe, 2017-2032 (USD Million)
TABLE 253. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 254. Middle East Drugs for the Treatment of Refractory Gout Market Size, by Vial, 2017-2032 (USD Million)
TABLE 255. Africa Drugs for the Treatment of Refractory Gout Market Size, by Region, 2017-2032 (USD Million)
TABLE 256. Africa Drugs for the Treatment of Refractory Gout Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 257. Africa Drugs for the Treatment of Refractory Gout Market Size, by Uricase Agents, 2017-2032 (USD Million)
TABLE 258. Africa Drugs for the Treatment of Refractory Gout Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 259. Africa Drugs for the Treatment of Refractory Gout Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 260. Africa Drugs for the Treatment of Refractory Gout Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 261. Africa Drugs for the Treatment of Refractory Gout Market Size, by Branded, 2017-2032 (USD Million)
TABLE 262. Africa Drugs for the Treatment of Refractory Gout Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 263. Africa Drugs for the Treatment of Refractory Gout Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 264. Africa Drugs for the Treatment of Refractory Gout Market Size, by Oral, 2017-2032 (USD Million)
TABLE 265. Africa Drugs for the Treatment of Refractory Gout Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 266. Africa Drugs for the Treatment of Refractory Gout Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 267. Africa Drugs for the Treatment of Refractory Gout Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 268. Africa Drugs for the Treatment of Refractory Gout Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 269. Africa Drugs for the Treatment of Refractory Gout Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 270. Africa Drugs for the Treatment of Refractory Gout Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 271. Africa Drugs for the Treatment of Refractory Gout Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 272. Africa Drugs for the Treatment of Refractory Gout Market Size, by Capsule, 2017-2032 (USD Million)
TABLE 273. Africa Drugs for the Treatment of Refractory Gout Market Size, by Pre Filled Syringe, 2017-2032 (USD Million)
TABLE 274. Africa Drugs for the Treatment of Refractory Gout Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 275. Africa Drugs for the Treatment of Refractory Gout Market Size, by Vial, 2017-2032 (USD Million)
TABLE 276. Global Drugs for the Treatment of Refractory Gout Market Size, by Group, 2017-2032 (USD Million)
TABLE 277. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Group, 2017-2032 (USD Million)
TABLE 278. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 279. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Uricase Agents, 2017-2032 (USD Million)
TABLE 280. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 281. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 282. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 283. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Branded, 2017-2032 (USD Million)
TABLE 284. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 285. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 286. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Oral, 2017-2032 (USD Million)
TABLE 287. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 288. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 289. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 290. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 291. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 292. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 293. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 294. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Capsule, 2017-2032 (USD Million)
TABLE 295. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Pre Filled Syringe, 2017-2032 (USD Million)
TABLE 296. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 297. ASEAN Drugs for the Treatment of Refractory Gout Market Size, by Vial, 2017-2032 (USD Million)
TABLE 298. GCC Drugs for the Treatment of Refractory Gout Market Size, by Group, 2017-2032 (USD Million)
TABLE 299. GCC Drugs for the Treatment of Refractory Gout Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 300. GCC Drugs for the Treatment of Refractory Gout Market Size, by Uricase Agents, 2017-2032 (USD Million)
TABLE 301. GCC Drugs for the Treatment of Refractory Gout Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 302. GCC Drugs for the Treatment of Refractory Gout Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 303. GCC Drugs for the Treatment of Refractory Gout Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 304. GCC Drugs for the Treatment of Refractory Gout Market Size, by Branded, 2017-2032 (USD Million)
TABLE 305. GCC Drugs for the Treatment of Refractory Gout Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 306. GCC Drugs for the Treatment of Refractory Gout Market Size, by Intravenous, 2017-2032 (USD Million)
TABLE 307. GCC Drugs for the Treatment of Refractory Gout Market Size, by Oral, 2017-2032 (USD Million)
TABLE 308. GCC Drugs for the Treatment of Refractory Gout Market Size, by Subcutaneous, 2017-2032 (USD Million)
TABLE 309. GCC Drugs for the Treatment of Refractory Gout Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 310. GCC Drugs for the Treatment of Refractory Gout Market Size, by Hospital Pharmacy, 2017-2032 (USD Million)
TABLE 311. GCC Drugs for the Treatment of Refractory Gout Market Size, by Online Pharmacy, 2017-2032 (USD Million)
TABLE 312. GCC Drugs for the Treatment of Refractory Gout Market Size, by Retail Pharmacy, 2017-2032 (USD Million)
TABLE 313. GCC Drugs for the Treatment of Refractory Gout Market Size, by Specialty Pharmacy, 2017-2032 (USD Million)
TABLE 314. GCC Drugs for the Treatment of Refractory Gout Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 315. GCC Drugs for the Treatment of Refractory Gout Market Size, by Capsule, 2017-2032 (USD Million)
TABLE 316. GCC Drugs for the Treatment of Refractory Gout Market Size, by Pre Filled Syringe, 2017-2032 (USD Million)
TABLE 317. GCC Drugs for the Treatment of Refractory Gout Market Size, by Tablet, 2017-2032 (USD Million)
TABLE 318. GCC Drugs for the Treatment of Refractory Gout Market Size, by Vial, 2017-2032 (USD Million)
TABLE 319. European Union Drugs for the Treatment of Refractory Gout Market Size, by Group, 2017-2032 (USD Million)
TABLE 320. European Union Drugs for the Treatment of Refractory Gout Market Size, by Mechanism Of Action, 2017-2032 (USD Million)
TABLE 321. European Union Drugs for the Treatment of Refractory Gout Market Size, by Uricase Agents, 2017-2032 (USD Million)
TABLE 322. European Union Drugs for the Treatment of Refractory Gout Market Size, by Uricosuric Agents, 2017-2032 (USD Million)
TABLE 323. European Union Drugs for the Treatment of Refractory Gout Market Size, by Xanthine Oxidase Inhibitors, 2017-2032 (USD Million)
TABLE 324. European Union Drugs for the Treatment of Refractory Gout Market Size, by Product Type, 2017-2032 (USD Million)
TABLE

Companies Mentioned

  • Amgen Inc.
  • Arthrosi Therapeutics, Inc.
  • AstraZeneca plc
  • Atom Bioscience and Pharmaceutical Co., Ltd.
  • Cartesian Therapeutics, Inc.
  • GlaxoSmithKline plc
  • InventisBio, Inc.
  • JW Pharmaceutical Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Olatec Therapeutics LLC
  • Pfizer Inc.
  • Protalix BioTherapeutics, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Shanton Pharma, Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Teijin Pharma Limited
  • XORTX Therapeutics Inc.

Related Topics

Related Reports

Gout Therapeutics Market - Global Forecast 2026-2032 - Product Image

Gout Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Interleukin Inhibitors for the Treatment of Refractory Gout Market - Global Forecast 2026-2032 - Product Image

Interleukin Inhibitors for the Treatment of Refractory Gout Market - Global Forecast 2026-2032

  • Report
  • 192 Pages
  • Global
From
Chronic Gout - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Chronic Gout - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 200 Pages
  • Global
From
Global Chronic Gout Market: Focus on Drug Class, Disease Type, Distribution Channel, Country, and Region - Analysis and Forecast, 2026-2036 - Product Image

Global Chronic Gout Market: Focus on Drug Class, Disease Type, Distribution Channel, Country, and Region - Analysis and Forecast, 2026-2036

  • Report
  • Global
From
Gout Therapeutics - Global Strategic Business Report - Product Image

Gout Therapeutics - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.